Compare · CELC vs CI
CELC vs CI
Side-by-side comparison of Celcuity Inc. (CELC) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELC and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $73.81B, about 16.3x CELC ($4.51B).
- CELC has been more active in the news (8 items in the past 4 weeks vs 7 for CI).
- CI has more recent analyst coverage (25 ratings vs 14 for CELC).
- Company
- Celcuity Inc.
- The Cigna Group
- Price
- $92.20+1.30%
- $279.37-0.35%
- Market cap
- $4.51B
- $73.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 8
- 7
- Recent ratings
- 14
- 25
Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest CELC
- Chief Science Officer Laing Lance G. was granted 20,000 shares, increasing direct ownership by 2% to 1,271,000 units (SEC Form 4)
- Chief Executive Officer Sullivan Brian F. was granted 80,000 shares, increasing direct ownership by 6% to 1,450,199 units (SEC Form 4)
- Chief Financial Officer Hahne Vicky was granted 16,000 shares, increasing direct ownership by 73% to 37,808 units (SEC Form 4)
- SEC Form 10-Q filed by Celcuity Inc.
- Celcuity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form SCHEDULE 13G filed by Celcuity Inc.
- Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
- Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
- SEC Form SCHEDULE 13G filed by Celcuity Inc.
Latest CI
- SEC Form 4 filed by Officer Holgerson Bryan
- Officer Jones Nicole S sold $748,516 worth of shares (2,677 units at $279.61) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 25,880 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- Officer Jones Nicole S exercised 15,346 shares at a strike of $192.02 and sold $5,369,584 worth of shares (19,436 units at $276.27) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 28,557 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- The Cigna Group downgraded by Jefferies with a new price target
- The Cigna Group downgraded by Raymond James with a new price target
- SEC Form 10-Q filed by The Cigna Group
- The Cigna Group filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- The Cigna Group Reports Strong Second Quarter 2026 Results, Raises 2026 Outlook